纳武利尤单抗在经重度预处理头颈癌患者中实现持久颅内和颅外缓解并出现继发性耐药
一例PD-L1阴性转移性头颈鳞癌患者,经西妥昔单抗为基础的化疗进展后接受三线纳武利尤单抗治疗,获得局部和全身显著缓解,包括脑转移灶完全失活持续超过一年。进展肿瘤病灶的活检显示T细胞浸润增加及T细胞耗竭和PD-1抑制耐药相关基因上调。
要点
- PD-L1阴性头颈鳞癌患者仍可能对PD-(L)1抑制剂产生持久缓解。
- 纳武利尤单抗可使头颈鳞癌脑转移灶完全失活并持续超过一年。
- 获得性耐药机制涉及T细胞浸润增加及T细胞耗竭和耐药相关基因上调。
核心结论
- 生物标志物阴性的头颈鳞癌中可观察到对PD-(L)1抑制剂的持久缓解。
- 应研究PD-(L)1抑制剂获得性耐药的机制。
研究设计与样本
- 病例报告:一例PD-L1阴性转移性头颈鳞癌患者,经西妥昔单抗为基础的化疗进展后接受三线纳武利尤单抗治疗。
- 比较纳武利尤单抗治疗前后进展肿瘤病灶活检的T细胞浸润和免疫相关基因mRNA表达。
主要发现
- 获得局部和全身显著缓解,包括脑转移灶完全失活持续超过一年。
- 进展肿瘤病灶活检显示T细胞浸润增加。
- 进展肿瘤病灶活检显示T细胞耗竭和PD-1抑制耐药相关基因上调。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recently, nivolumab was approved in the second-line setting of squamous cell cancer of the head and neck (SCCHN). The benefits of PD-(L)1 inhibitors in PD-L1(-) tumors are unclear, and no reports exist on the activity of these agents in brain metastases from SCCHN. Little is known regarding the mechanisms underlying acquired resistance to PD-(L)1 inhibition. METHODS: A patient with PD-L1(-) metastatic SCCHN progressing to cetuximab-based chemotherapy received third-line nivolumab. T cell infiltration and mRNA expression of immune-related genes were compared in prenivolumab and postnivolumab biopsies from a progressing tumor lesion. RESULTS: An exceptional local and systemic response was achieved, including complete devitalization of brain metastases that lasted for more than a year. Increased T cell infiltration and upregulation of genes related to T cell exhaustion and resistance to PD-1 inhibition were found. CONCLUSION: Durable responses to PD-(L)1 inhibitors may be observed in biomarker-negative SCCHN. Mechanisms of resistance should be studied.
引用
- Cabezas-Camarero S, García-Barberán V, Sáiz-Pardo Sanz M, et al. Durable intracranial and extracranial response to nivolumab with appearance of secondary resistance in a heavily pretreated patient with head and neck cancer. Head Neck. 2019. PMID: 30652379. doi:10.1002/hed.25635
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。